Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMMUNEPOTENT CRP
- Development stage
- Phase 2
- Lead developer
- Universidad Autónoma de Nuevo León
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Peptides
- Administration
- Topical, Intramuscular, Intravenous
01
Overview
IMMUNEPOTENT CRP is a bovine dialyzable leukocyte extract (bDLE) derived from bovine spleens, containing a complex mixture of low-molecular-weight substances including transfer factors. It functions as an unspecific active immunotherapy and immunomodulator with both antitumor and pro-regenerative properties. In oncology, it induces immunogenic cell death (ICD) by triggering endoplasmic reticulum calcium release via IP3 and ryanodine receptors, leading to reactive oxygen species (ROS) production and mitochondrial damage, often bypassing traditional caspase-dependent apoptotic pathways. It has been evaluated in Phase I clinical trials as an adjuvant to chemotherapy (such as cisplatin) in non-small cell lung cancer to enhance efficacy and mitigate myelosuppression. Additionally, recent research has explored exosomes derived from IMMUNEPOTENT CRP for accelerating diabetic wound healing through the modulation of the PI3K-AKT pathway and inflammatory cytokine profiles.
- Brand names
- IMMUNEPOTENT CRP
- Other names
- bovine dialyzable leukocyte extractbDLEbovine spleen leukocyte extracttransfer factor
02
Targets
IP3R (Inositol Trisphosphate Receptor)RYR2 (Ryanodine receptor 2)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on IMMUNEPOTENT CRP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMMUNEPOTENT CRP.